Annual CFF
$360.00 K
+$210.00 K+140.00%
31 December 2023
Summary:
Enlivex Therapeutics annual cash flow from financing activities is currently $360.00 thousand, with the most recent change of +$210.00 thousand (+140.00%) on 31 December 2023. During the last 3 years, it has fallen by -$32.72 million (-98.91%). ENLV annual CFF is now -99.41% below its all-time high of $60.98 million, reached on 31 December 2021.ENLV Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$4.42 M
+$3.90 M+743.32%
30 June 2024
Summary:
Enlivex Therapeutics quarterly cash flow from financing activities is currently $4.42 million, with the most recent change of +$3.90 million (+743.32%) on 30 June 2024. Over the past year, it has increased by +$4.42 million (+100.00%). ENLV quarterly CFF is now -92.75% below its all-time high of $60.92 million, reached on 31 March 2021.ENLV Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$4.94 M
+$4.38 M+773.32%
30 June 2024
Summary:
Enlivex Therapeutics TTM cash flow from financing activities is currently $4.94 million, with the most recent change of +$4.38 million (+773.32%) on 30 June 2024. Over the past year, it has increased by +$4.58 million (+1273.06%). ENLV TTM CFF is now -93.09% below its all-time high of $71.54 million, reached on 31 March 2021.ENLV TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENLV Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +140.0% | +100.0% | +1273.1% |
| 3 y3 years | -98.9% | +6495.5% | -93.1% |
| 5 y5 years | -93.1% | +641.4% | -40.8% |
ENLV Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.4% | +140.0% | at high | >+9999.0% | -93.1% | +4161.2% |
| 5 y | 5 years | -99.4% | +140.0% | -92.8% | >+9999.0% | -93.1% | +4161.2% |
| alltime | all time | -99.4% | -92.8% | +4268.9% | -93.1% | +4719.6% |
Enlivex Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | $4.42 M(+743.3%) | $4.94 M(+773.3%) |
| Mar 2024 | - | $524.00 K(>+9900.0%) | $566.00 K(+57.2%) |
| Dec 2023 | $360.00 K(+140.0%) | $0.00(0.0%) | $360.00 K(0.0%) |
| Sept 2023 | - | $0.00(-100.0%) | $360.00 K(-12.2%) |
| June 2023 | - | $42.00 K(-86.8%) | $410.00 K(-1.9%) |
| Mar 2023 | - | $318.00 K(>+9900.0%) | $418.00 K(+178.7%) |
| Dec 2022 | $150.00 K(-99.8%) | $0.00(-100.0%) | $150.00 K(+2.0%) |
| Sept 2022 | - | $50.00 K(0.0%) | $147.00 K(-10.4%) |
| June 2022 | - | $50.00 K(0.0%) | $164.00 K(+41.4%) |
| Mar 2022 | - | $50.00 K(-1766.7%) | $116.00 K(-99.8%) |
| Dec 2021 | $60.98 M(+84.3%) | -$3000.00(-104.5%) | $60.98 M(-14.7%) |
| Sept 2021 | - | $67.00 K(+3250.0%) | $71.51 M(+0.1%) |
| June 2021 | - | $2000.00(-100.0%) | $71.45 M(-0.1%) |
| Mar 2021 | - | $60.92 M(+478.6%) | $71.54 M(+116.3%) |
| Dec 2020 | $33.08 M(+298.3%) | $10.53 M(>+9900.0%) | $33.08 M(+46.7%) |
| Sept 2020 | - | $0.00(-100.0%) | $22.55 M(-2.6%) |
| June 2020 | - | $97.00 K(-99.6%) | $23.15 M(-11.1%) |
| Mar 2020 | - | $22.46 M(>+9900.0%) | $26.05 M(+213.6%) |
| Dec 2019 | $8.31 M(+59.9%) | $0.00(-100.0%) | $8.31 M(-0.6%) |
| Sept 2019 | - | $596.00 K(-80.1%) | $8.36 M(-35.2%) |
| June 2019 | - | $3.00 M(-36.3%) | $12.90 M(+30.3%) |
| Mar 2019 | - | $4.71 M(+9322.0%) | $9.90 M(+90.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $5.19 M(-35.5%) | $50.00 K(-99.0%) | $5.19 M(-60.6%) |
| Sept 2018 | - | $5.14 M(>+9900.0%) | $13.20 M(+63.9%) |
| June 2018 | - | $0.00(0.0%) | $8.05 M(0.0%) |
| Mar 2018 | - | $0.00(-100.0%) | $8.05 M(0.0%) |
| Dec 2017 | $8.05 M(+32.3%) | $8.05 M(>+9900.0%) | $8.05 M(<-9900.0%) |
| Sept 2017 | - | $0.00(0.0%) | -$1000.00(0.0%) |
| June 2017 | - | $0.00(0.0%) | -$1000.00(-99.1%) |
| Mar 2017 | - | $0.00(-100.0%) | -$107.00 K(-101.8%) |
| Dec 2016 | $6.09 M(>+9900.0%) | -$1000.00(<-9900.0%) | $6.09 M(-0.0%) |
| Sept 2016 | - | $0.00(-100.0%) | $6.09 M(0.0%) |
| June 2016 | - | -$106.00 K(-101.7%) | $6.09 M(-1.7%) |
| Mar 2016 | - | $6.20 M(>+9900.0%) | $6.20 M(>+9900.0%) |
| Dec 2015 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2015 | - | $0.00(0.0%) | -$70.00 K(-100.2%) |
| June 2015 | - | $0.00(0.0%) | $31.51 M(+0.1%) |
| Mar 2015 | - | $0.00(-100.0%) | $31.49 M(-14.4%) |
| Dec 2014 | $36.78 M(+3611.9%) | -$70.00 K(-100.2%) | $36.78 M(-0.2%) |
| Sept 2014 | - | $31.58 M(<-9900.0%) | $36.85 M(+598.8%) |
| June 2014 | - | -$20.00 K(-100.4%) | $5.27 M(-0.4%) |
| Mar 2014 | - | $5.29 M | $5.29 M |
| Dec 2013 | $991.00 K(+235.9%) | - | - |
| Dec 2012 | $295.00 K | - | - |
FAQ
- What is Enlivex Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Enlivex Therapeutics?
- What is Enlivex Therapeutics annual CFF year-on-year change?
- What is Enlivex Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Enlivex Therapeutics?
- What is Enlivex Therapeutics quarterly CFF year-on-year change?
- What is Enlivex Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Enlivex Therapeutics?
- What is Enlivex Therapeutics TTM CFF year-on-year change?
What is Enlivex Therapeutics annual cash flow from financing activities?
The current annual CFF of ENLV is $360.00 K
What is the all time high annual CFF for Enlivex Therapeutics?
Enlivex Therapeutics all-time high annual cash flow from financing activities is $60.98 M
What is Enlivex Therapeutics annual CFF year-on-year change?
Over the past year, ENLV annual cash flow from financing activities has changed by +$210.00 K (+140.00%)
What is Enlivex Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ENLV is $4.42 M
What is the all time high quarterly CFF for Enlivex Therapeutics?
Enlivex Therapeutics all-time high quarterly cash flow from financing activities is $60.92 M
What is Enlivex Therapeutics quarterly CFF year-on-year change?
Over the past year, ENLV quarterly cash flow from financing activities has changed by +$4.42 M (+100.00%)
What is Enlivex Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ENLV is $4.94 M
What is the all time high TTM CFF for Enlivex Therapeutics?
Enlivex Therapeutics all-time high TTM cash flow from financing activities is $71.54 M
What is Enlivex Therapeutics TTM CFF year-on-year change?
Over the past year, ENLV TTM cash flow from financing activities has changed by +$4.58 M (+1273.06%)